WuXi Biologics

WuXi Biologics today announced an agreement with Candid Therapeutics, a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases. Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal multispecific antibody platform WuXiBody™. #TCE #trispecific #multispecific #WuXiBody #antibody For more information, please visit: https://lnkd.in/gsYsqgTe

Let's connect during the JPM Week 2025 (January 13-16) in San Francisco, CA. Our team will be available the full week to discuss partering needs for your cutting-edge technologies and latest breakthroughs. Contact us through the partneringONE system and we'll set up a convenient time to discuss the potential for partnering with us. You may also request a meeting here: https://lnkd.in/gvNFGynY #JPMWeek2025 #SanFrancisco #Biotech #HealthcareInnovation #PartnershipOpportunities #NetworkingEvent #LifeSciences #HealthcareTechnology #InnovateTogether

Clinical In-Use (CIU) studies are typically conducted during biotherapeutic development to assess the stability and compatibility of the biological product with administration components and/or diluents. These studies simulate product use in clinical practice, generating experimental data to ensure patient safety and product efficacy during administration. Our Clinical In-Use Center of Excellence (CIU CoE) offers comprehensive services, including customized study design for multiple administration routes, analytical testing across a wide dosing range from ng to mg, an extensive inventory of diverse CIU consumables, and global support for IND & BLA filings. https://lnkd.in/eUQJugYB #drugproducts #drugformulation #drugproductdevelopment

Facility Spotlight: Let us help you realize your breakthrough biological treatment from concept to clinical trials and beyond - discovered, developed, and manufactured here in the United States. Start your discovery project at our Boston Research Service Center and then move on to CMC development and clinical manufacturing conducted in facilities that are in close proximity along the east coast. Contact us now to start your journey! https://lnkd.in/e4G3if6 #biomanufacturing #gmpmanufacturing #biopharmaceutical #drugdevelopment #drugmanufacturing #mammalian #cellculture #cmcdevelopment #biologics

Happy New Year 2025! 🎉 Just before the holidays, WuXi Biologics was featured in the Irish Independent’s Future of Manufacturing Campaign, highlighting our Dundalk facility's role in Ireland’s biopharma ecosystem. In the article, our leaders—Brendan McGrath, Eimear McCarron, and Gene Russell —share their perspectives on how we’re advancing large-scale manufacturing, upholding world-class quality standards, and driving sustainability. From innovative single-use technology to our commitment to reducing environmental impact, the piece reflects how we’re shaping the future of biopharma with purpose and precision. Full article: https://lnkd.in/euNebkia Q&A: https://lnkd.in/enV54kKV

WuXi Biologics today announced that it has been named to the 2024 Dow Jones Sustainability Indices (DJSI), and given among the top scores for its unremitting efforts and notable achievements in promoting sustainable development. #ESG #sustainability #DJSI #CRDMO For more information, please visit: https://lnkd.in/gW5ZaVYC

🎄✨ Happy New Year from WuXi Biologics! ✨🎄 As we wrap up another incredible year, we want to extend our heartfelt gratitude to our clients and partners worldwide. Your trust and collaboration have been the cornerstone of our success, and we are truly honored to support your journey in advancing biologics. May this holiday season bring you joy, peace, and cherished moments with your loved ones. 🌟 Cheers to a bright and prosperous 2025! 🌟 #HappyHolidays #WuXiBiologics #ThankYou

🏎 Harness the safety, flexibility, and efficacy of messenger RNA (mRNA) without the complication. After the COVID-19 vaccine amplified interest in this crucial intermediary between DNA and protein synthesis, its utility has continued to flourish. Get it on this booming modality with comprehensive support from WuXi Biologics. Our ✨expert service✨ takes you from DNA to IND and IND to BLA with the utmost quality and latest technology. To learn more, visit https://lnkd.in/ecVwjjwh. #mRNA #mRNAvaccine #LNP #plasmid #DNA #bioprocessing #biomanufacturing #biopharma #biologics #biotherapeutics

Whether you are developing products from mammalian cell culture, microbial fermentation or via in vitro methodologies, choose our Late Stage Development and Commercialization Services to help you meet your critical BLA filing milestones.  Our highly-vetted streamlined development platforms are designed to accelerate your product through all aspects of late phase process, assay and formulation development, optimization, characterization and validation.  Reach out now to redefine and expedite your path to BLA. https://lnkd.in/eDVs8zYe #CellCulture #MicrobialFermentation #ProductDevelopment #LateStageDevelopment #BLA #AssayDevelopment #FormulationDevelopment

WuXi Biologics today announced that it has signed a service agreement with Sino Biopharm, a leading innovative R&D-driven pharmaceutical group in China, to discover a first-in-class mAb against an undisclosed target. 🎇Sino Biopharm will have the exclusive rights to the mAb against undisclosed target, derived from WuXi Biologics' integrated discovery technology platforms 🎇WuXi Biologics introduces new tailored service-based mode in integrated discovery services to enable client's global strategies #research #antibody #mAb #firstinclass For more information, please visit: https://lnkd.in/gxS_3f7K